DNA methylation in the CTCF-binding site I and the expression pattern of the H19 gene: Does positive expression predict poor prognosis in early stage head and neck carcinomas?

Molecular Carcinogenesis

Volumn 44, Issue 2, 2005, Pages 102-110

  Esteves, Leda I C V ^a   Javaroni, Afonso C ^b   Nishimoto, Inês N ^c   Magrin, José ^c   Squire, Jeremy A ^d   Kowalski, Luiz P ^c   Rainho, Claudia A ^a   Rogatto, Silvia R ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b Amaral Carvalho Hospital   (Brazil)

^c A C CAMARGO CANCER CENTER   (Brazil)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Differentially methylated region; Imprinted gene; Tumor progression; Tumor suppressor gene

Indexed keywords

DNA; TUMOR MARKER;

ADULT; AGED; ALLELISM; ARTICLE; BINDING SITE; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DNA METHYLATION; FEMALE; FISHER EXACT TEST; GENE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC ANALYSIS; GENOME IMPRINTING; H19 GENE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IGF2 GENE; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TUMOR RECURRENCE;

ADULT; AGED; BINDING SITES; CARCINOMA; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; GENOMIC IMPRINTING; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REPRESSOR PROTEINS; RNA, UNTRANSLATED;

EID: 25844447788     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20126     Document Type: Article

References (54)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-194.
2. Franceschi S, Bidoli E, Herrero R, Munoz N. Comparison of cancers of the oral cavity and pharynx worldwide: Etiological clues. Oral Oncol 2000;36:106-115.
3. Wunsch-Filho V. The epidemiology of oral and pharynx cancer in Brazil. Oral Oncol 2002;38:737-746.
4. Franco EL, Kowalski LP, Oliveira BV, et al. Risk factors for oral cancer in Brazil: A case-control study. Int J Cancer 1989; 43:992-1000.
5. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85.
6. Miracca EC, Yamamoto L, Contado D, Takimoto MSS, Kowalski LP, Nagai MA. Distinct chromosomal deleted regions defining different subsets of head and neck tumors. Diagn Mol Pathol 2000;9:229-233.
7. Mondal G, Tripathi A, Bhattacharya N, et al. Allelic imbalance at chromosome 11 in head and neck squamous cell carcinoma in an Indian patient population. J Clin Pathol 2003;56: 512-518.
8. El-Naggar AK, Hurr K, Huff V, Luna MA, Goepfert H, Batsakis JG. Allelic loss and replication errors at microsatellite loci on chromosome 11p in head and neck squamous carcinoma: Association with aggressive biological features. Clin Cancer Res 1996;2:903-907.
9. Viel A, Giannini F, Tumiotto L, Sopracordevole F, Visentin C, Boiocchi M. Chromosomal localization of two putative 11p oncosuppressor genes involved in human ovarian tumours. Br J Cancer 1992;66:1030-1036.
10. Tran YK, Newsham IF. High-density marker analysis of 11p15.5 in non-small cell lung carcinomas reveals allelic deletion of one shared and one distinct region when compared to breast carcinomas. Cancer Res 1996;56:2916-2921.
11. Bernard-Guérin C, Newsham I, Winqwist R, Cavenee WK. Population variation at the polymorphic ApaI restriction enzyme site in intron 5 of the WT1 gene. Hum Genet 1996; 97:163-170.
12. Koi M, Johnson LA, Kalikin LM, Little PFR, Nakamura Y, Feinberg AP. Tumor cell growth arrest caused by subchromosomal transferable DNA fragments from chromosome 11. Science 1993;260:361-364.
13. Lichy JH, Zavar M, Tsai MM, O'Leary TJ, Taubenberger JK. Loss of heterozygosity on chromosome 11p15 during histological progression in microdissected ductal carcinoma of the breast. Am J Pathol 1998;153:271-278.
14. Feinberg AP. Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: An introduction. Cancer Res 1999;59:1743s-1746s.
15. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6-21.
16. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-1080.
17. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 2002;3:662-673.
18. Reik W, Murrel A. Genomic imprinting: Silence across the border. Nature 2000;405:408-409.
19. Ohlsson R, Nystrom A, Pfeifer-Ohlsson S, et al. IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome. Nat Genet 1993;4: 94-97.
20. Rachmilewitz J, Goshen R, Ariel I, Schneider T, de Groot N, Hochberg A. Parental imprinting of the human H19 gene. FEBS Lett 1992;309:25-28.
21. Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B. Tumour-suppressor activity of H19 RNA. Nature 1993;365: 764-767.
22. Wrana JL. H19, a tumour suppressing RNA? Bioassays 1994; 16:89-90.
23. Thorvaldsen JL, Duran KL, Bartolomei MS. Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and IGF2. Genes Dev 1998;12: 3693-3702.
24. Bell AC, Felsenfeld G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 2000;405:482-485.
25. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 2000;405: 486-489.
26. Ohlsson R, Renkawitz R, Lobanenkov V. CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet 2001;17:520-527.
27. Li X, Kogner P, Sandstedt B, Haas AO, Ekström TJ. Promoter-specific methylation and expression alterations of igf2 and h19 are involved in human hepatoblastoma. Int J Cancer 1998;75:176-180.
28. El-Naggar AK, Lai S, Tucker Sa, et al. Frequent loss of imprinting at the IGF2 and H19 genes in head and neck squamous carcinoma. Oncogene 1999;18:7063-7069.
29. Rainho CA, Kowalski LP, Rogatto SR. Loss of imprinting and loss of heterozygosity on 11p15.5 in head and neck squamous cell carcinomas. Head Neck 2001;23:851-859.
30. Lai S, Goepfert H, Gillenwater AM, Luna MA, El-Naggar AK. Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57KIP2 gene in head and neck squamous cell carcinoma. Clin Cancer Res 2000;6:3172-3176.
31. World Health Organization: International Classification of Diseases for Oncology, 2nd edn. Geneva: World Health Organization; 1990.
32. American Joint Committee on Cancer: Manual for Staging of Cancer. Philadelphia: J.B. Lippincott; 2002.
33. Zhang Y, Tycko B. Monoallelic expression of the human H19 gene. Nat Genet 1992;1:40-44.
34. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992;89:1827-1831.
35. Ewing B, Green P. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res 1998; 8:186-194.
36. Ewing B, Hillier I, Wendl MC, Green P. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 1998;8:175-185.
37. Grunau C, Schattevory R, Mache N, Rosenthal A. Meth-Tools-A toolbox to visualize and analyze DNA methylation data. Nucleic Acid Res 2000;28:1053-1058.
38. Warnecke PM, Stizaker C, Song J, Grunau C, Melki JR, Clarck S. Identification and resolution of artifacts in bisulfite sequencing. Methods 2002;27:101-107.
39. Bockmuhl U, Wolf G, Schmidt S, et al. Genomic alterations associated with malignancy in head and neck cancer. Head Neck 1998;20:145-151.
40. Ripoche NA, Kress C, Poirrer F, Dandolo L. Deletion of the H19 transcription unit reveals the existence of a putative imprinting control element. Genes Dev 1997;11:1596-1604.
41. Moulton T, Crenshaw T, Hao Y, et al. Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat Genet 1994;7: 440-447.
42. Fukuzawa R, Umezawa A, Ochi K, Urano F, Ikeda H, Hata J. High frequency of inactivation of the imprinted H19 gene in "sporadic" hepatoblastoma. Int J Cancer 1999;82:490-497.
43. Ulaner GA, Vu Th, Li T, et al. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet 2003; 12:535-549.
44. Cui H, Niemitz EL, Ravenel JD, et al. Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site. Cancer Res 2001;61:4947-4950.
45. Szyf M. Targeting DNA methylation in cancer. Ageing Res Rev 2003;2:299-328.
46. Takay D, Gonzales FA, Tsai YC, Thayer MJ, Jones P. Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Hum Mol Genet 2001;10:2619-2626.
47. Nakagawa H, Chadwick RB, Peltomäki P, Plass C, Nakamura Y, de la Chapelle A. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci USA 2001;98:591-596.
48. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 2002;62:6442-6446.
49. Kondo M, Suzuki H, Ueda R, et al. Frequent loss of imprinting of the H19 gene is often associated with its over-expression in human lung cancers. Oncogene 1995;19: 1193-1198.
50. Hibi K, Nakamura H, Hirai A, et al. Loss of H19 imprinting in esophageal cancer. Cancer Res 1996;56:480-482.
51. Ariel I, Lustig O, Schneider T, et al. The imprinted H19 gene as a tumor marker in bladder carcinoma. Urology 1995;45: 335-338.
52. Ariel I, Sughayer M, Felling Y, et al. The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. Mol Pathol 2000;54:320-323.
53. Adrienssens E, Dumont L, Lottin S, et al. H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and ki-67 expression. Am J Pathol 1998;153:1597-1607.
54. Ayesh S, Matouk I, Schneider T, et al. Possible physiological role of H19 RNA. Mol Carcinog 2002;35:63-74.